References in periodicals archive ?
This agreement enables Sanofi-Pasteur to implement the StabyExpress technology in its production of recombinant vaccines and therefore to be able to produce them efficiently without using antibiotic markers.
The inclusion of these antibiotic markers have been strongly opposed especially because it is possible for this genetic material to move to bacteria in the soil or from the genetically engineered food into gut bacteria, increasing the possibility of antibiotic resistance.
Although there is limited knowledge about the risk of compromising the therapeutic value of antibiotics, antibiotic markers may be banned in agricultural crops in the future (Kuiper et al., 2001; Miki and McHugh, 2004).

Full browser ?